The Importance of Addressing Multidrug Resistance and Not Assuming Single-Drug Resistance in Case-Control Studies
- 1 July 2006
- journal article
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 27 (7) , 670-674
- https://doi.org/10.1086/505917
Abstract
Background.: Case-control studies analyzing antibiotic exposure as a risk factor for antimicrobial resistance usually assume single-drug resistance in the bacteria under study, even though resistance to multiple antimicrobials may be present. Since antibiotic selection pressures differ depending on the susceptibility profile of the antimicrobial-resistant bacteria, an accurate assessment of whether exposure to an individual antimicrobial is a risk factor for the emergence of resistance should distinguish between single-drug–resistant and multidrug-resistant bacteria.Objective.: To determine whether the exposures to individual antibiotics that were identified as independent risk factors in case-control studies differed depending on whether single-drug–resistant or multidrug-resistant bacteria were evaluated.Design.: Two retrospective case-control studies were performed with data on patients harboringPseudomonas aeruginosastrains resistant only to ciprofloxacin (CRPA) and patients harboringP. aeruginosastrains resistant to ciprofloxacin and other antibiotics (multidrug-resistantP. aeruginosa[MDR-PA]). These 2 groups were compared with patients not harboringP. aeruginosa.Setting.: Two tertiary care hospitals.Results.: A total of 41 patients harboring CRPA and 151 patients harboring MDR-PA were identified and matched to 192 control subjects. By conditional logistic regression, independent risk factors associated with presence of CRPA were nonambulatory status (OR, 5.6 [95% confidence interval {CI}, 1.4-23];P= .02) and prior ciprofloxacin exposure (OR, 5.0 [95% CI, 1.2-21];P= .03). Independent risk factors for presence of MDR-PA were a Charlson score greater than 2 (OR, 3.3 [95% CI 1.8-6.0];P<.001) and exposure to quinolones (OR, 2.8 [95% CI, 1.2-5.0];P= .001), third- and fourth-generation cephalosporins (OR, 3.5 [95% CI, 1.7-7.1];P<.001), imipenem (OR, 3.8 [95% CI, 1.2-12.1];P= .02), and/or aminoglycosides (OR, 2.3 [95% CI, 1.04-5.1];P= .04).Conclusion.: There were substantial differences in exposure to individual antimicrobials between patients harboring CRPA and patients harboring MDR-PA. Future case-control studies addressing risk factors for single-drug–resistant bacteria should consider the complete susceptibility profile of the bacteria under investigation.Keywords
This publication has 19 references indexed in Scilit:
- The Case-Case-Control Study Design: Addressing the Limitations of Risk Factor Studies for Antimicrobial ResistanceInfection Control & Hospital Epidemiology, 2005
- Methodologic issues of case-control studies: a review of established and newly recognized limitations.Infection Control & Hospital Epidemiology, 2005
- Impact of Severity of Illness Bias and Control Group Misclassification Bias in Case-Control Studies of Antimicrobial-Resistant OrganismsInfection Control & Hospital Epidemiology, 2005
- Rapidly Rising Prevalence of Nosocomial Multidrug-Resistant, Gram-Negative Bacilli: A 9-Year Surveillance StudyInfection Control, 2004
- Risk factors for multidrug-resistant Pseudomonas aeruginosa nosocomial infectionJournal of Hospital Infection, 2004
- Risk factors and clinical outcomes of nosocomial multi-drug resistant Pseudomonas aeruginosa infectionsJournal of Hospital Infection, 2004
- Pseudomonas aeruginosaVentilator‐Associated Pneumonia: Comparison of Episodes Due to Piperacillin‐Resistant versus Piperacillin‐Susceptible OrganismsClinical Infectious Diseases, 2002
- Risk Factors for Piperacillin-Tazobactam-Resistant Pseudomonas aeruginosa among Hospitalized PatientsAntimicrobial Agents and Chemotherapy, 2002
- Multidrug-Resistant Pseudomonas Aeruginosa Bloodstream Infections: Analysis of Trends in Prevalence and EpidemiologyEmerging Infectious Diseases, 2002
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987